Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin glargine + exenatide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Insulin glargine + exenatide is a combination therapy used in the management of type 2 diabetes mellitus. Insulin glargine is a long-acting recombinant human insulin analog that provides basal glycemic control by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. Exenatide is a glucagon-like peptide 1 (GLP‑1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. The combination aims to improve both fasting and postprandial blood glucose levels in patients with type 2 diabetes who have inadequate glycemic control on oral agents or monotherapy[4][5][6][8].
- Brand names
- LantusBasaglarToujeoSemgleeRezvoglar
- Other names
- insulin glargine + exenatide
02
Targets
GLP1R (GLP-1R)INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin glargine + exenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin glargine + exenatide.